By The Life Science Report
Source: Streetwise Reports 01/16/2019
A LifeSci Capital report discussed two current trials in which this therapeutic is being evaluated.
In a Jan. 14 research note, analyst Sam Slutsky reported the Phase 2 EMERGE clinical trial evaluating 4SC AG’s (VSC:FSE Prime Standard) domatinostat with Bavencio (avelumab) in patients with microsatellite-stable esophagogastric cancer and colorectal cancer.
Enrollment of patients, which will total up to 70, started at the first study locations. The goal of the trial is to show safety of the combination therapies and generate proof-of-concept data. Initial results could be released in H2/19.
“This event marks continuing progress in the development of domatinostat,” Slutsky pointed out. This selective histone deacetylase inhibitor is now being evaluated in combination with Keytruda in SENSITIVE, an ongoing Phase 1b/2 trial in melanoma that is refractory/unresponsive to anti-PD-1. A third dose cohort in SENSITIVE got underway recently, after the second dose group showed a positive safety profile and the Safety Review Committee, in December 2018, recommended proceeding. Topline results from SENSITIVE are expected in mid-2019.
Should data from EMERGE and SENSITIVE be positive, 4SC plans to pursue a trial evaluating the combination of domatinostat and a checkpoint inhibitor in advanced Merkel cell carcinoma (MCC), wrote Slutsky. Preclinical MCC data are expected in H1/19.
4SC’s stock is currently trading at around 3.10 per share.
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are sponsors of Streetwise Reports: None. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases.
Disclosures from LifeSci Capital, 4SC AG, Company Update, January 14, 2019
Analyst Certification: The research analyst denoted by an “AC” on the cover of this report certifies (or, where multiple research analysts are primarily responsible for this report, the research analyst denoted by an “AC” on the cover or within the document individually certifies), with respect to each security or subject company that the research analyst covers in this research, that: (1) all of the views expressed in this report accurately reflect his or her personal views about any and all of the subject securities or subject companies, and (2) no part of any of the research analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the research analyst(s) in this report.
Neither the research analyst(s), a member of the research analyst’s household, nor any individual directly involved in the preparation of this report has a financial interest in the securities of the subject company.
LSC (or an affiliate) has received compensation from 4SC AG for producing this research report. LSC is paid a monthly payment of $1,000 from the Affiliate for preparing and distributing research pertaining to each subject company under contract with the Affiliate. The subject company of this report is covered by this arrangement between LSC and the Affiliate, and LSC has therefore indirectly received compensation from the subject company for publishing this report. No explicit or implicit promises of favorable research coverage have been made to the subject company by LSC or the Affiliate. Neither LSC nor the Affiliate has promised any specific research content as an inducement for the receipt of business or compensation.
LSC (or an affiliate) has also provided non-investment banking securities-related services, non-securities services, and other products or services other than investment banking services to 4SC AG and received compensation for such services within the past 12 months.
Neither LSC nor any of its affiliates beneficially own 1% or more of any class of common equity securities of the subject company.
This research contains the views, opinions and recommendations of LifeSci Capital, LLC (“LSC”) research analysts.
Additionally, LSC expects to receive or intends to seek compensation for investment banking services from the subject company/ companies in the next three months.
LSC does not make a market in the securities of the subject company/companies.
Please visit http://www.lifescicapital.com/equity-research/ for disclosures related to each company that is a subject of this report.
( Companies Mentioned: VSC: FSE Prime Standard,